Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (99)

« Back to Publications

Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.

Coleman RL. et al, (2026), Diabetes Obes Metab, 28, 1068 - 1075

International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL.

Clarke PM. et al, (2025), Diabetes Care, 48, 1925 - 1931

Assessing the efficacy, safety and utility of hybrid closed-loop glucose control compared with standard insulin therapy combined with continuous glucose monitoring in young people (≥16 years) and adults with cystic fibrosis-related diabetes (CL4P-CF study): protocol for an open-label, multicentre, randomised, two-arm and single-period parallel trial

Kadiyala N. et al, (2025), BMJ Open, 15

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.

Coleman RL. et al, (2025), Cardiovasc Diabetol, 24

Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023).

Golubic R. et al, (2025), Diabetes Obes Metab, 27, 3635 - 3644

Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.

Maddaloni E. et al, (2025), Diabetes Res Clin Pract, 223

Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

Golubic R. et al, (2025), Diabet Med, 42

The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.

Adler AI. et al, (2025), Lancet, 405

Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).

Lin B. et al, (2024), Lancet Diabetes Endocrinol, 12, 904 - 914

Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.

Oulhaj A. et al, (2024), Diabetes Obes Metab, 26, 4602 - 4612

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).

Adler AI. et al, (2024), Lancet, 404, 145 - 155

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.

Morrow LM. et al, (2024), J Diabetes, 16

Effect of once-weekly exenatide on, and risk factors for, bone fractures in type 2 diabetes: an EXSCEL clinical trial post-hoc analysis

Maddaloni E. et al, (2024), DIABETOLOGIA, 67, S517 - S518

Young-Onset Type 2 Diabetes-UK Prospective Diabetes Trial (UKPDS) 30-Year Follow-up

Lin B. et al, (2024), DIABETES, 73

Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.

Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471

Load More

1
2
3
4
5
6
7